TransMedics Q1 Earnings Miss Expectations, Shares Drop 19%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy TMDX?
Source: seekingalpha
- Earnings Miss: TransMedics reported adjusted earnings of $0.30 per share for Q1, falling short of analyst expectations by $0.31, leading to a 19% drop in premarket trading, indicating market concerns over the company's profitability.
- Stable Revenue Growth: Despite the disappointing earnings, TransMedics achieved a 21.2% year-over-year revenue increase to $173.9 million, aligning with estimates, which suggests strong market demand for its organ transplant technology.
- Sharp Decline in Net Income: The company's net income plummeted to $7.3 million, or $0.20 per diluted share, down from $25.7 million and $0.70 a year earlier, reflecting the impact of rising growth costs and supply chain pressures.
- Unchanged Full-Year Outlook: TransMedics reaffirmed its 2026 revenue guidance of $727 million to $757 million, projecting a 20% to 25% growth despite a soft market backdrop, demonstrating management's confidence in future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMDX
Wall Street analysts forecast TMDX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 72.900
Low
115.00
Averages
147.80
High
170.00
Current: 72.900
Low
115.00
Averages
147.80
High
170.00
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TransMedics Reports Strong Q1 Growth with $174M Revenue
- Significant Revenue Growth: TransMedics Group Inc reported total revenue of $174 million for Q1 2026, reflecting a 21% year-over-year increase, which underscores the company's strong market performance and sustained demand, further solidifying its leadership in the organ transplant sector.
- International Market Expansion: The company is actively expanding into international markets, particularly in Europe, with plans to replicate its successful U.S. logistics model, which not only enhances global market share but also strengthens brand presence and customer base.
- Strong Financial Position: TransMedics maintains $462 million in cash and cash equivalents, ensuring continued investment in technology, infrastructure, and international expansion, thereby laying a solid foundation for future growth.
- Operational Challenges and Investment Pressure: Despite a gross margin of approximately 58% in Q1, down 331 basis points year-over-year due to increased internal supply chain activities and investments, the company faces competitive pressures from clinical programs, with expectations of operating margins falling below last year's levels, highlighting the challenges encountered during expansion.
See More
Stock Investment Opportunities in May
- TransMedics' Bright Outlook: Despite TransMedics Group (NASDAQ: TMDX) reporting Q1 earnings per share of $0.30, below the expected $0.61, its revenue increased by 21% year-over-year, indicating strong long-term potential in organ transplant technology, especially with plans for European expansion.
- Rhythm Pharmaceuticals' Recovery: Rhythm Pharmaceuticals (NASDAQ: RYTM) recently secured FDA and European Commission approvals for Imcivree, which is expected to boost its stock price, while Japanese regulators are also reviewing the drug, impacting over 25,000 patients and highlighting significant market potential.
- Enbridge's Stable Returns: Enbridge (NYSE: ENB), as North America's largest natural gas utility, transports 30% of crude oil and one-fifth of natural gas, providing stable investment returns, with an attractive 5.2% dividend yield that stands out in the energy sector.
- Long-Term Growth Opportunities: Enbridge's management anticipates approximately $50 billion in growth opportunities by 2030, with investment decisions for $10 billion to $20 billion expected in the next 24 months, offering solid growth prospects despite being less explosive than TransMedics and Rhythm.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
US Stocks Surge to New Highs Led by Tech Earnings
- Tech Stock Rally: The Nasdaq 100 index surged over 1.44% to reach an all-time high, driven by strong earnings from chipmakers and AI infrastructure stocks, reflecting market optimism about sustained investment growth in artificial intelligence.
- Crude Oil Plunge: WTI crude oil prices fell more than 6% to a two-week low as the US nears a peace agreement with Iran, which is expected to lift restrictions on the Strait of Hormuz, thereby reducing energy costs and enhancing profitability prospects for airlines and cruise lines.
- Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, suggesting a lower likelihood of interest rate hikes.
- Earnings Optimism: So far, 84% of the 375 S&P 500 companies that reported earnings have exceeded expectations, with Q1 earnings projected to rise 12% year-over-year, indicating strong corporate profitability that further supports the stock market's upward trend.
See More
US Stocks Reach All-Time Highs as AI Investments Surge
- Market Performance: The S&P 500 index rose by 0.76% and the Nasdaq 100 index increased by 1.19%, reaching all-time highs, reflecting strong market optimism regarding ongoing investments in artificial intelligence, which are expected to continue driving stock prices higher.
- Chipmakers' Strong Earnings: Advanced Micro Devices (AMD) saw its stock price surge over 16% after raising its full-year sales forecast significantly due to robust data center spending, indicating a strong growth trajectory and reinforcing its competitive position in the semiconductor market.
- Crude Oil Price Plunge: WTI crude oil prices fell more than 5% to a two-week low as the US nears a peace agreement with Iran, which may help lower inflation expectations and improve profitability prospects for airlines and cruise operators amid declining fuel costs.
- Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, which is likely to continue supporting stock market gains.
See More
TransMedics Q1 Earnings Miss Expectations, Shares Drop 19%
- Earnings Miss: TransMedics reported adjusted earnings of $0.30 per share for Q1, falling short of analyst expectations by $0.31, leading to a 19% drop in premarket trading, indicating market concerns over the company's profitability.
- Stable Revenue Growth: Despite the disappointing earnings, TransMedics achieved a 21.2% year-over-year revenue increase to $173.9 million, aligning with estimates, which suggests strong market demand for its organ transplant technology.
- Sharp Decline in Net Income: The company's net income plummeted to $7.3 million, or $0.20 per diluted share, down from $25.7 million and $0.70 a year earlier, reflecting the impact of rising growth costs and supply chain pressures.
- Unchanged Full-Year Outlook: TransMedics reaffirmed its 2026 revenue guidance of $727 million to $757 million, projecting a 20% to 25% growth despite a soft market backdrop, demonstrating management's confidence in future growth prospects.
See More
TransMedics Reports Strong Q1 Growth with $174M Revenue
- Significant Revenue Growth: TransMedics Group Inc reported total revenue of $174 million for Q1 2026, reflecting a 21% year-over-year increase, which underscores the company's strong market performance and sustained demand, further solidifying its leadership in the organ transplant sector.
- International Market Expansion: The company is actively expanding into international markets, particularly in Europe, with plans to replicate its successful U.S. logistics model, which not only enhances global market share but also strengthens brand presence and customer base.
- Strong Financial Position: TransMedics maintains $462 million in cash and cash equivalents, ensuring continued investment in technology, infrastructure, and international expansion, thereby laying a solid foundation for future growth.
- Operational Challenges and Investment Pressure: Despite a gross margin of approximately 58% in Q1, down 331 basis points year-over-year due to increased internal supply chain activities and investments, the company faces competitive pressures from clinical programs, with expectations of operating margins falling below last year's levels, highlighting the challenges encountered during expansion.
See More
Stock Investment Opportunities in May
- TransMedics' Bright Outlook: Despite TransMedics Group (NASDAQ: TMDX) reporting Q1 earnings per share of $0.30, below the expected $0.61, its revenue increased by 21% year-over-year, indicating strong long-term potential in organ transplant technology, especially with plans for European expansion.
- Rhythm Pharmaceuticals' Recovery: Rhythm Pharmaceuticals (NASDAQ: RYTM) recently secured FDA and European Commission approvals for Imcivree, which is expected to boost its stock price, while Japanese regulators are also reviewing the drug, impacting over 25,000 patients and highlighting significant market potential.
- Enbridge's Stable Returns: Enbridge (NYSE: ENB), as North America's largest natural gas utility, transports 30% of crude oil and one-fifth of natural gas, providing stable investment returns, with an attractive 5.2% dividend yield that stands out in the energy sector.
- Long-Term Growth Opportunities: Enbridge's management anticipates approximately $50 billion in growth opportunities by 2030, with investment decisions for $10 billion to $20 billion expected in the next 24 months, offering solid growth prospects despite being less explosive than TransMedics and Rhythm.
See More
US Stocks Surge as Tech Stocks Lead Gains
- Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
- Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
- Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
- International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
See More
US Stocks Surge to New Highs Led by Tech Earnings
- Tech Stock Rally: The Nasdaq 100 index surged over 1.44% to reach an all-time high, driven by strong earnings from chipmakers and AI infrastructure stocks, reflecting market optimism about sustained investment growth in artificial intelligence.
- Crude Oil Plunge: WTI crude oil prices fell more than 6% to a two-week low as the US nears a peace agreement with Iran, which is expected to lift restrictions on the Strait of Hormuz, thereby reducing energy costs and enhancing profitability prospects for airlines and cruise lines.
- Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, suggesting a lower likelihood of interest rate hikes.
- Earnings Optimism: So far, 84% of the 375 S&P 500 companies that reported earnings have exceeded expectations, with Q1 earnings projected to rise 12% year-over-year, indicating strong corporate profitability that further supports the stock market's upward trend.
See More
US Stocks Reach All-Time Highs as AI Investments Surge
- Market Performance: The S&P 500 index rose by 0.76% and the Nasdaq 100 index increased by 1.19%, reaching all-time highs, reflecting strong market optimism regarding ongoing investments in artificial intelligence, which are expected to continue driving stock prices higher.
- Chipmakers' Strong Earnings: Advanced Micro Devices (AMD) saw its stock price surge over 16% after raising its full-year sales forecast significantly due to robust data center spending, indicating a strong growth trajectory and reinforcing its competitive position in the semiconductor market.
- Crude Oil Price Plunge: WTI crude oil prices fell more than 5% to a two-week low as the US nears a peace agreement with Iran, which may help lower inflation expectations and improve profitability prospects for airlines and cruise operators amid declining fuel costs.
- Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, which is likely to continue supporting stock market gains.
See More
TransMedics Q1 Earnings Miss Expectations, Shares Drop 19%
- Earnings Miss: TransMedics reported adjusted earnings of $0.30 per share for Q1, falling short of analyst expectations by $0.31, leading to a 19% drop in premarket trading, indicating market concerns over the company's profitability.
- Stable Revenue Growth: Despite the disappointing earnings, TransMedics achieved a 21.2% year-over-year revenue increase to $173.9 million, aligning with estimates, which suggests strong market demand for its organ transplant technology.
- Sharp Decline in Net Income: The company's net income plummeted to $7.3 million, or $0.20 per diluted share, down from $25.7 million and $0.70 a year earlier, reflecting the impact of rising growth costs and supply chain pressures.
- Unchanged Full-Year Outlook: TransMedics reaffirmed its 2026 revenue guidance of $727 million to $757 million, projecting a 20% to 25% growth despite a soft market backdrop, demonstrating management's confidence in future growth prospects.
See More
